A Safety and Immunogenicity Phase 1 Trial With an Adjuvanted TB Subunit Vaccine (Ag85B-ESAT-6 + IC31) Administered in Different Antigen/Adjuvant Formulations in TST Negative and TST Positive Volunteers at 0 and 2 Months.
Phase of Trial: Phase I
Latest Information Update: 18 Jan 2013
At a glance
- Drugs H1IC (Primary) ; Tuberculosis vaccine
- Indications Tuberculosis
- Focus Adverse reactions
- 07 Feb 2012 Actual patient number (39) added as reported by ClinicalTrials.gov.
- 07 Feb 2012 Actual end date (Apr 2010) added as reported by ClinicalTrials.gov.
- 07 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.